Print

Teva Pharmaceutical Industries Limited (TEVA) Appoints Michael Hayden as President of Global Research and Development and Chief Scientific Officer  
5/9/2012 10:42:27 AM

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that Dr. Michael R. Hayden, will join the company as the President of Global Research and Development and Chief Scientific Officer, based in Israel. In this new role, Dr. Hayden will lead all research and development for Teva, thus combining the efforts of two world-class teams focused on the development of both brand and generic medicines.
//-->